John Hodgson, St. Joseph’s Hospital and Medical Center, Phoenix American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta The TYPHOON study from...
March, 2006
Pexelizumab Reduces Mortality in High Risk Coronary Artery By-Pass Patients+
Peter Smith, Duke University Medical Center, Durham, NC Late Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006 The drug pexelizumab, targeting inflammation,...
Salt Substitute Substantially Lowers Blood Pressure Among High-Risk Individuals+
Bruce Neal, The George Institute, University of Sydney Late Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006 Because high levels of salt...
CHARISMA Trial: Add Clopidogrel to Aspirin? Not for Lower Risk Patients+
Deepak Bhatt, Cleveland Clinic, Ohio American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta The idea of adding clopidogrel anti-platelet therapy to...
Single Agent Bivalirudin Better for Acute Coronary Syndromes+
Gregg Stone, Columbia University Medical Center, New York American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta A superiority for the anti-clotting...
Bivalirudin in ACS: The Acuity Study Findings+
Michael Lincoff, Cleveland Clilnic, Cleveland Ohio American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta The full picture of how bivalirudin is...
Audio Journal of Oncology 14.2, March 2006+
Reporting from: American Society of Hematology Meeting, Atlanta, 10-13 December 2005 In this edition: It is not necessary to use rituximab along with standard...
Pregnancy Risk from Cervical Excision+
Maria Kyrgiou, Hammersmith Hospital, London Abstract: Lancet 2006; 367: 489-98 A meta-analysis published in the Lancet has found that excising pre-cancerous lesions of the...
Natalizumab Risks and Benefits in Multiple Sclerosis+
Chris Polman, Free University of Amsterdam Abstract N Engl J Med 2006;345:899 Despite fears that natalizumab – which reduces progression in some categories of...